Frontlight ResearchEarly access
TerminatedPhase 2
Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors
Key facts
- Who runs it
- Memorial Sloan Kettering Cancer Center
- Where
- New York, United StatesSee the site
- Trial code
- Status
- Terminated
- Phase
- Phase 2
- People taking part
- 9 people enrolled
- Started
- 25 Jul 2018
- Ended
- 6 Mar 2024
- Type of study
- Interventional, 3 groups
- Treatments tested
- Hyperfractionated total body irradiation
- Thiotepa
- Cyclophosphamide
- Busulfan
- Fludarabine
- Melphalan
- Clofarabine
- HPC(A) stem cell allograft
- Rituximab
- Rabbit antithymocyte globulin
- Record updated
- 6 April 2025
- Why it stopped
- Low accrual
Who can take part
- Age
- Up to 65 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 24 criteriaShow less
Other criteria
- Subject Inclusion Criteria:
- Patients with any of the following hematologic malignancies who are considered to be eligible for allogeneic transplantation:; Acute lymphoid leukemia (ALL) in first complete remission (CR1) with high risk for relapse including:; Detectable minimal residual disease by either multicolor flow cytometry or by genomic assay after initial induction therapy; t(9;22) or detected BCR-ABL1 translocation by genomic methodologies; BCR-ABL1-Like B-ALL [23] including mutations of IKZF1 or CRLF2; Translocations or mutations involving 11q23 (MLL) gene; Hypodiploid karyotype; Deletion of 9p; Loss of 17p or TP53 mutation; T-lymphocyte lineage antigen expression (T-ALL); Prior CNS or other extramedullary involvement; WBC count ≥ 100,000 cells/μL at diagnosis; Acute biphenotypic or bilineal leukemia in CR1; Acute myeloid leukemia (AML) in CR1 with; Detectable minimal residual disease (MRD) by either multicolor flow cytometry or by genomic assay after initial induction therapy; In the absence of MRD any intermediate or high risk features according to the European LeukemiaNet 2017 guidelines indlucing:
- Mutated FL T3-ITD or FL T3-TKD
- Cytogenetic abnormalities not classified as favorable
- Cytogenetic abnormalities associated with myelodysplastic syndrome including abnormalities of chromosome 5, 7, or 17p
- Complex karyotype or monosomal karyotype
- t(9;11)(p21.1;q23.3); MLL-KMT2A or other rearrangements of KMT2A
- t(9;11); BCR-ABL1
- Inversions or translocations of chromosome 3
- T(6;9)(p23;q34.1); DEK-NUP214
- Somatic mutation of RUNX1, ASX1 or TP53; Extramedullary involvement; WBC count ≥100,000 cells/μL at diagnosis; Relapsed acute leukemia with ≤ 5% blasts in the bone marrow prior to transplantation (i.e. CR2 or greater); Myelodysplastic syndrome, myeloproliferative neoplasms, or MDS/MPN overlap syndrome with ≤ 10% blasts and at least one of the following:; Revised International Prognostic Scoring System risk score of INT, HIGH, or VERY HIGH at the time of transplant evaluation; Life-threatening cytopenias; Karyotype or genomic changes that indicate high risk for progression to acute myelogenous leukemia, including abnormalities of chromosome 7 or 3, mutations of TP53, or complex or monosomal karyotype; Therapy related disease or disease evolving from other malignant processes; Chronic myelomonocytic leukemia (CMML) with ≤ 10% blasts prior to transplantation; Chronic myeloid leukemia (CML) meeting one of the following criteria:; Failed or are intolerant to BCR-ABL tyrosine kinase inhibitors; CML with BCR-ABL mutation consistent with poor response to tyrosine kinase inhibition (e.g. T351I mutation); CML with accelerated or blast phase with <10% blasts after therapy; Chronic lymphocytic leukemia (CLL) with high risk disease as defined by the EBMT consensus criteria; Hodgkin lymphoma meeting both of the following criteria:; Responding to therapy prior to enrollment; Relapse after autologous bone marrow transplant or are ineligible for autologous bone marrow transplant; °Non-Hodgkin lymphoma meeting both of the following criteria:; Responding to therapy prior to enrollment; Relapse after prior autologous bone marrow transplant or are ineligible for autologous bone marrow transplant; Patients aged from birth through 65 years old are eligible; Patients must have Karnofsky/Lanksy performance status ≥70%; Cardiac left ventricular ejection fraction ≥50% at rest; Serum bilirubin ≤ 2 mg/dL. Patients with Gilbert's disease or ongoing hemolytic anemia are acceptable if the direct bilirubin is ≤ 2 mg/dL; AST and ALT ≤ 2.5 x ULN unless thought to be disease related; Estimated or measured creatinine clearance > 50 mL/min/1.73 m\^2 body surface area; Adult patients and pediatric patients capable of performing pulmonary function studies must have hemoglobin adjusted pulmonary DLCO ≥50% of predicted; Subject Exclusion Criteria:
- Persons with a HLA matched sibling donor or a 8/8 allele level HLA-matched unrelated donor
- Female patients who are pregnant or breast-feeding
- Persons with an infection that is not responding to antimicrobial therapy
- Persons who are seropositive for HIV
- Persons with active/detectable central nervous system malignancy
- Persons who do not meet the age and organ function criteria specified above
- Presence of psychiatric or neurologic disease, or lack of social support that limits the patient's ability to comply with the treatment protocol including supportive care, followup, and research tests
- Prior allogeneic hematopoietic cell transplantation are ineligible
- Patients with history of other malignancy within 5 years of study therapy are ineligible with the following exceptions: Low grade prostate cancer (Gleason's ≤6) treated with curative intent, breast ductal carcinoma in situ treated with curative intent, or nonmelanomatous skin carcinomas; Donor Inclusion and Exclusion Criteria:
- Partially HLA-matched unrelated volunteers (allele level matched at 6-7 of 8 HLA loci: -A, -B, -C, and -DRB1) are eligible
- Related, haploidentical donors are eligible
- Able to provide informed consent to the donation process
- Meet standard criteria for donor collection as defined by the National Marrow Donor Program Guidelines
Where in United States
- Memorial Sloan-Kettering Cancer CenterNew York, United States
About the trial
What the trial wants to find out
This study is being done to learn whether a new method to prevent rejection between the donor immune system and the patient's body is effective.
The 3 groups in the trial
- Radiation, Thiotepa & CyclophosphamideTreatment being tested
Treatment: Hyperfractionated total body irradiation, Thiotepa, Cyclophosphamide, HPC(A) stem cell allograft, Rituximab, and Rabbit antithymocyte globulin
- Busulfan, Fludarabine & MelphalanTreatment being tested
Treatment: Busulfan, Fludarabine, Melphalan, HPC(A) stem cell allograft, Rituximab, and Rabbit antithymocyte globulin
- Clofarabine, Thiotepa & MelphalanTreatment being tested
Treatment: Thiotepa, Melphalan, Clofarabine, HPC(A) stem cell allograft, Rituximab, and Rabbit antithymocyte globulin
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Allogeneic Hematopoietic Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors
- Record updated
- 6 April 2025